MaxCyte Inc. (MXCT)
| Bid | 2.72 |
| Market Cap | 288.93M |
| Revenue (ttm) | 38.6M |
| Net Income (ttm) | -41.03M |
| EPS (ttm) | -0.4 |
| PE Ratio (ttm) | -6.81 |
| Forward PE | -12.66 |
| Analyst | Buy |
| Ask | 2.88 |
| Volume | 220,795 |
| Avg. Volume (20D) | 623,545 |
| Open | 2.79 |
| Previous Close | 2.82 |
| Day's Range | 2.70 - 2.81 |
| 52-Week Range | 2.70 - 5.26 |
| Beta | 1.20 |
About MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale...
Analyst Forecast
According to 2 analyst ratings, the average rating for MXCT stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 266.97% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MaxCyte, Inc. (NASDAQ: MXCT) concerning the Company and its directors' and officers' possible violations o...
